- Home
- ZNTL vs NRIM Comparison
ZNTL vs NRIM Comparison
Compare ZNTL & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- NRIM
- Stock Information
- Founded
- ZNTL 2014
- NRIM 1990
- Country
- ZNTL United States
- NRIM United States
- Employees
- ZNTL N/A
- NRIM N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- NRIM Savings Institutions
- Sector
- ZNTL Health Care
- NRIM Finance
- Exchange
- ZNTL Nasdaq
- NRIM Nasdaq
- Market Cap
- ZNTL 238.2M
- NRIM 369.8M
- IPO Year
- ZNTL 2020
- NRIM N/A
- Fundamental
- Price
- ZNTL $3.12
- NRIM $69.40
- Analyst Decision
- ZNTL Buy
- NRIM
- Analyst Count
- ZNTL 7
- NRIM 0
- Target Price
- ZNTL $10.86
- NRIM N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- NRIM 23.6K
- Earning Date
- ZNTL 11-04-2024
- NRIM 10-28-2024
- Dividend Yield
- ZNTL N/A
- NRIM 3.63%
- EPS Growth
- ZNTL N/A
- NRIM 13.73
- EPS
- ZNTL N/A
- NRIM 5.78
- Revenue
- ZNTL $40,560,000.00
- NRIM $136,386,000.00
- Revenue This Year
- ZNTL N/A
- NRIM N/A
- Revenue Next Year
- ZNTL N/A
- NRIM $3.03
- P/E Ratio
- ZNTL N/A
- NRIM $11.78
- Revenue Growth
- ZNTL N/A
- NRIM 6.71
- 52 Week Low
- ZNTL $2.83
- NRIM $38.65
- 52 Week High
- ZNTL $18.24
- NRIM $74.34
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- NRIM 50.80
- Support Level
- ZNTL $2.92
- NRIM $68.06
- Resistance Level
- ZNTL $3.23
- NRIM $73.14
- Average True Range (ATR)
- ZNTL 0.17
- NRIM 1.54
- MACD
- ZNTL 0.00
- NRIM -0.04
- Stochastic Oscillator
- ZNTL 38.33
- NRIM 45.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The company operates in two segments: Community Banking and Home Mortgage Lending. It generates maximum revenue from the Community Banking segment. It offers to spend and save products such as checking, savings, money market accounts, debit cards, cashback rewards, and credit cards. It also includes loans and credit lines, mortgage loans, investment, and plan products.